U.S. Markets open in 2 hrs 21 mins
  • S&P Futures

    3,670.50
    +16.25 (+0.44%)
     
  • Dow Futures

    29,387.00
    +102.00 (+0.35%)
     
  • Nasdaq Futures

    11,271.00
    +42.75 (+0.38%)
     
  • Russell 2000 Futures

    1,692.40
    +10.30 (+0.61%)
     
  • Crude Oil

    81.47
    +0.24 (+0.30%)
     
  • Gold

    1,674.20
    +5.60 (+0.34%)
     
  • Silver

    19.00
    +0.29 (+1.57%)
     
  • EUR/USD

    0.9760
    -0.0059 (-0.6051%)
     
  • 10-Yr Bond

    3.7470
    0.0000 (0.00%)
     
  • Vix

    31.31
    +1.13 (+3.74%)
     
  • GBP/USD

    1.1061
    -0.0063 (-0.5619%)
     
  • USD/JPY

    144.5400
    +0.0970 (+0.0672%)
     
  • BTC-USD

    19,476.49
    +64.10 (+0.33%)
     
  • CMC Crypto 200

    445.24
    -0.74 (-0.17%)
     
  • FTSE 100

    6,912.63
    +31.04 (+0.45%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Recap: Baxter International Q4 Earnings

·1 min read

 

Shares of Baxter International (NYSE:BAX) moved higher by 0.3% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 1700.00% over the past year to $0.80, which beat the estimate of $0.76.

Revenue of $3,181,000,000 rose by 4.67% year over year, which beat the estimate of $3,040,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $3.35 and $3.43.

The upcoming fiscal year's revenue expected to be between $12,490,000,000 and $12,607,000,000.

Details Of The Call

Date: Feb 04, 2021

View more earnings on BAX

Time: 08:30 AM

ET Webcast URL: https://www.directeventreg.com/der/validateConferenceId.action

Recent Stock Performance

52-week high: $95.19

Company's 52-week low was at $69.10

Price action over last quarter: down 0.10%

Company Description

Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2019 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (25% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.